可切除及交界可切除胰腺癌的短程或全新辅助化疗——现状与未来展望
Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.
作者信息
Labori Knut Jørgen
机构信息
Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
出版信息
Front Surg. 2022 Apr 25;9:839339. doi: 10.3389/fsurg.2022.839339. eCollection 2022.
Abstract
Neoadjuvant therapy improves overall survival compared with a surgery-first approach in patients with borderline resectable pancreatic cancer (BRPC). Evidence of higher quality is required to determine whether neoadjuvant therapy has potential benefits and improves survival for patients with resectable pancreatic cancer (RPC). Most randomized controlled trials (RCTs) have explored short-course neoadjuvant chemotherapy (SNT), but total neoadjuvant chemotherapy (TNT) is now the experimental arm of ongoing RCTs. This article reviews the current status of SNT and TNT in RPC and BRPC, and provides perspectives of future challenges and research directions in this field.
摘要
与手术优先的方法相比，新辅助治疗可提高临界可切除胰腺癌（BRPC）患者的总生存率。需要更高质量的证据来确定新辅助治疗是否对可切除胰腺癌（RPC）患者具有潜在益处并提高生存率。大多数随机对照试验（RCT）都探索了短程新辅助化疗（SNT），但全程新辅助化疗（TNT）目前是正在进行的RCT的试验组。本文综述了RPC和BRPC中SNT和TNT的现状，并提供了该领域未来挑战和研究方向的观点。
相似文献
1
Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives.
Front Surg. 2022 Apr 25;9:839339. doi: 10.3389/fsurg.2022.839339. eCollection 2022.
2
Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Eur J Clin Pharmacol. 2023 Mar;79(3):323-340. doi: 10.1007/s00228-022-03441-9. Epub 2022 Dec 28.
3
Neoadjuvant chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Meta-analysis and trial sequential analysis of randomized controlled trials.
Ann Hepatobiliary Pancreat Surg. 2023 Feb 28;27(1):28-39. doi: 10.14701/ahbps.22-052. Epub 2022 Dec 20.
4
Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
Front Oncol. 2022 Feb 14;11:744161. doi: 10.3389/fonc.2021.744161. eCollection 2021.
5
Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
World J Surg Oncol. 2019 Dec 31;18(1):1. doi: 10.1186/s12957-019-1767-5.
6
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.
7
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
Int J Surg Protoc. 2021 Apr 26;25(1):55-60. doi: 10.29337/ijsp.142.
8
Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.
J Gastrointest Oncol. 2022 Apr;13(2):885-897. doi: 10.21037/jgo-21-829.
9
Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
Pancreas. 2016 Nov;45(10):1438-1446. doi: 10.1097/MPA.0000000000000634.
10
Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):74-79. doi: 10.1016/j.hbpd.2020.08.001. Epub 2020 Aug 17.
引用本文的文献
1
Total Neoadjuvant Therapy in Localized Pancreatic Cancer: Is More Better?
Cancers (Basel). 2024 Jun 30;16(13):2423. doi: 10.3390/cancers16132423.
2
Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.
J Clin Med. 2023 Oct 11;12(20):6461. doi: 10.3390/jcm12206461.
3
Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress.
World J Gastrointest Surg. 2023 Feb 27;15(2):142-162. doi: 10.4240/wjgs.v15.i2.142.
4
3D Ultrasound-Guided Photoacoustic Imaging to Monitor the Effects of Suboptimal Tyrosine Kinase Inhibitor Therapy in Pancreatic Tumors.
Front Oncol. 2022 Jul 7;12:915319. doi: 10.3389/fonc.2022.915319. eCollection 2022.
本文引用的文献
1
Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
J Clin Oncol. 2022 Apr 10;40(11):1220-1230. doi: 10.1200/JCO.21.02233. Epub 2022 Jan 27.
2
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
Eur J Cancer. 2022 Jan;160:140-149. doi: 10.1016/j.ejca.2021.10.023. Epub 2021 Nov 24.
3
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.
Ann Surg Oncol. 2022 Mar;29(3):1579-1591. doi: 10.1245/s10434-021-10991-2. Epub 2021 Nov 1.
4
Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival.
Br J Surg. 2021 Dec 17;109(1):61-70. doi: 10.1093/bjs/znab229.
5
Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives.
Front Oncol. 2021 Jun 23;11:682872. doi: 10.3389/fonc.2021.682872. eCollection 2021.
6
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2021 Dec;28(13):8297-8308. doi: 10.1245/s10434-021-10276-8. Epub 2021 Jun 17.
7
The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review.
Ann Nucl Med. 2021 Jul;35(7):767-776. doi: 10.1007/s12149-021-01629-0. Epub 2021 May 28.
8
Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?
Cancers (Basel). 2021 Apr 20;13(8):1986. doi: 10.3390/cancers13081986.
9
Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
JAMA Surg. 2021 Jul 1;156(7):663-672. doi: 10.1001/jamasurg.2021.0149.
10
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
Ann Surg Oncol. 2021 Oct;28(11):6790-6802. doi: 10.1245/s10434-021-09823-0. Epub 2021 Mar 30.
Zotero 插件